KKL 顾客使用本产品发表的 0 篇科研文献

BAY-3827 is a potent and selective AMPK inhibitor with IC₅₀  values of 1.4 nM at low (10 µM ATP concentration) and 15 nM at high (2 mM ATP concentration). BAY-3827 shows over 500-fold selectivity for most of the 331 kinases. BAY-3827 prevents phosphorylation of acetyl-CoA carboxylase 1 and shows strongest anti-proliferative activity in androgen-dependent prostate cancer cell lines.

IC50: 1.4 nM (AMPK kinase,10 µM ATP), 15 nM (AMPK kinase, 2 mM ATP), 1324 nM (Aurora A), 124 nM (Flt3), 788 nM (c-Met), 36 nM (Rsk4)

BAY-3827 (0-200 μM) inhibits AMPK kinase activity with IC50 values of 1.4 nM and 15 nM, respectively, under low (10 μM) and high (2 mM) ATP conditions. BAY-3827 (0-200 μM) inhibited the activity of Aurora A, Flt3, c-Met, and Rsk4 under 10 μM ATP conditions, with IC50 values of 1324 nM, 124 nM, 788 nM, and 36 nM, respectively. BAY-3827 (overnight) significantly reduced the phosphorylation of ACC1 Ser79 in LNCaP and VCaP cells, with weaker effects in IMR-32 and Colo320 cells [1].
BAY-3827 (0-10 nM; 6 days) showed significant inhibitory effects on LNCaP and VCaP cells [1].
BAY-3827 (1 and 5 μM; Inhibiting LIPE gene expression at 24 and 48 hours, reducing the expression of serine/threonine kinase AKT3, and blocking the expression of several genes in the mitochondrial carnitine palmitoyltransferase (CPT) family involved in acylcarnitine formation in VCaP cells [1].
BAY-3827 (5 μM; 2-4 days) significantly increased lipid droplet formation in VCaP cells compared to androgen treatment alone [1].

Room temperature in continental US; may vary elsewhere.

2-8°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)